Developing a nanosensor platform to detect early signs of pancreatic cancer
Machine Perception Nanosensor Array Platform to Capture Whole Disease Fingerprints of Early Stage Pancreatic Cancer
This study is working on a new tool that can help doctors spot pancreatic cancer earlier by looking for unique signs in your blood, using tiny sensors to find differences that current tests might miss, so you can get the right treatment sooner.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Georgia Institute of Technology NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project ID | NIH-10994167 on NIH RePORTER |
What this research studies
This research focuses on creating a nanosensor array that can identify unique disease fingerprints from patient biofluids, specifically aimed at improving the early diagnosis of pancreatic cancer. By analyzing molecular interactions in blood serum, the project seeks to enhance the sensitivity and specificity of current biomarker tests, which are often inadequate for accurate disease assessment. The innovative use of carbon nanotubes and DNA stabilization aims to capture subtle differences in biofluid properties, potentially leading to better diagnostic tools for patients. If successful, this technology could significantly improve early detection rates, allowing for timely treatment options.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at high risk for pancreatic cancer or those experiencing symptoms related to the disease.
Not a fit: Patients with advanced pancreatic cancer or those who do not have pancreatic cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to earlier and more accurate diagnoses of pancreatic cancer, improving treatment outcomes for patients.
How similar studies have performed: Other research has shown promise in using nanosensor technologies for disease detection, indicating potential success for this novel approach.
Where this research is happening
Atlanta, United States
- Georgia Institute of Technology — Atlanta, United States (Active)
Researchers
- Principal investigator: Kim, Mijin — Georgia Institute of Technology
- Study coordinator: Kim, Mijin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.